<DOC>
	<DOCNO>NCT02707159</DOCNO>
	<brief_summary>The majority patient diagnose pancreatic cancer metastatic disease time diagnosis . The prognosis extremely poor 5-year survival rate le 5 % . Treatment chemotherapy improve efficacy , still median progression-free survival patient receive nab-paclitaxel gemcitabine 5,5 month median overall survival less one year . There urgent need tool predict efficacy treatment . The current trial aim investigate biomarker potential circulating tumor cell ( CTCs ) metastatic pancreatic cancer patient treat gemcitabine nab-paclitaxel .</brief_summary>
	<brief_title>Circulating Tumor Cells Tools Therapy Response Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Male female &gt; 18 year 80 year Histologically cytologically proven adenocarcinoma pancreas start treatment . Also patient strong suspicion unresectable pancreatic cancer diagnosis confirm asked consent take 2 additional biopsy time diagnostic biopsy retrieval , case histological analysis confirms include . Locally advance ( primarily unresectable ) and/or metastatic disease . Presence least one measurable lesion accord RECIST criterion , restrict previously irradiate area limit bone , pleural effusion ascites . ECOG/WHO performance status ≤2 Absolute neutrophil count ( ANC ) &gt; 1.5 x 109 /L platelet count &gt; 100 x 109/L Total bilirubin &lt; 1.5 time upper limit normal range institution ( ULN ) AST ALT &lt; 2 x ULN . If liver metastasis present , patient include total bilirubin &lt; 5× ULN AST/ALT &lt; 10× ULN . Dose reduction paclitaxel perform bilirubin &gt; 2xULN , depend increase bilirubin level accord recommendation Summary Product Characteristics . Serum creatinin &lt; 1,5 ULN / calculate creatine clearance &gt; 60 ml/min . Written inform consent Current infection , bowel obstruction subobstruction , uncontrolled intercurrent illness . Prior medical treatment advance pancreatic cancer Confirmed brain metastasis . Concurrent past history another malignancy except curatively treat nonmelanoma skin cancer situ carcinoma cervix . Treatment investigational drug 30 day prior study entry . Allergy anyone include drug . Female patient breast feed pregnancy Not able/ willing use adequate contraception ( define ) . A pregnancy test include baseline visit woman childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Circulating tumor cell</keyword>
	<keyword>Nab-paclitaxel</keyword>
	<keyword>Metastatic pancreatic cancer</keyword>
	<keyword>Gemcitabine</keyword>
</DOC>